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CNS = central nervous system; RASON = respirable antisense oligonucleotide.
Available online http://respiratory-research.com/content/2/1/005
Introduction
Antisense oligonucleotides have been called ‘the next
great wave of the biotechnology revolution’ and the ‘phar-
macology of the future’. Certainly from a theoretical point
of view, the antisense approach, in which the target phar-
macophore is a specific sequence found in a specific
mRNA, should have several advantages over traditional
pharmaceuticals, which target proteins. The most obvious
potential advantage is that interdiction occurs at a point
more proximal to the cause of the disease — the (usually)
discordantly expressed mRNA — rather than the protein
already participating in the disease process. Other poten-
tial advantages of targeting mRNA instead of protein
include the following:
1. Increased specificity and avidity. Antisense oligonu-
cleotides can bind (‘hybridize’) to their mRNA targets
with much greater specificity and with much greater
avidity than can traditional drugs to their protein
targets. This is because the sum of the hydrogen
bonding between the oligonucleotide and its mRNA
target exceeds by several orders of magnitude the Van
der Waals and other forces with which traditional
drugs bind to proteins.
2. Ability to prescreen for non-target hybridization.
Because an antisense oligonucleotide targets a spe-
cific sequence (essentially a one-dimensional target)
rather than a complex three-dimensional amino acid
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domain, it becomes possible to screen in advance of
toxicology studies for hybridization potential to non-
target mRNAs. This can be accomplished for known
genes by database scanning, and for unknown genes
by northern and Southern blotting techniques. Such an
advantage in predictive toxicology is not available in
the development of traditional drugs, which target
complex three-dimensional domains within proteins.
The complexity of such protein domains at present pre-
vents any meaningful a priori identification of interac-
tion of a drug candidate with non-target proteins.
3. Markedly different target properties. The attenuation of
a target mRNA population might require much longer
periods to recover to disease-causing levels than inhi-
bition at the protein level, as exemplified by studies on
EPI-2010 (see below). This feature can translate into
markedly longer durations of effect after the attenua-
tion of a specific mRNA via the antisense approach in
comparison with the inhibition, with traditional drugs, of
the protein coded for by the same mRNA.
4. Rapid development. Antisense therapeutics can be
designed and tested much more quickly and rationally
than traditional drugs, with antisense libraries consis-
tently showing success rates several orders of magni-
tude greater than for traditional libraries. The success
rate for traditional libraries, that is, the chance of
finding, via large-scale screening, a compound that will
bind to a target protein, has been cited as being as
high as 0.02% [1]. Compare this with a consistently
reported success rate of approximately 10% for anti-
sense libraries. The potential benefits, in terms of a
reduction in development times and an acceleration of
the rate of making drugs available to the patients who
need them, are enticing from both economic and
medical perspectives.
Thus, there are many reasons why antisense oligonu-
cleotides could be a potential breakthrough in technology
for the more rapid and more economic development of
highly specific, effective drugs. Nevertheless, it should
also be pointed out that not every potential respiratory
target is likely to represent a target for which the antisense
approach is optimal. Considerations such as quantity and
half-life of the mRNA and protein of the target are likely to
be important determinants of whether the antisense
approach will work or not. Other considerations related to
the successful therapeutic application of this class of mol-
ecules include the potential to induce immunologic effects
with particular nucleotide backbone structures or
sequence motifs.
The practical application of antisense oligonucleotide
technology has been impeded by several factors. The first
of these, the ubiquitous presence of nucleases that can
degrade oligonucleotides quite readily, has been success-
fully addressed by a number of chemical modifications
that inhibit susceptibility to cellular nucleases [2,3].
Recent advances in oligonucleotide chemistry have
included chimeric oligonucleotides that incorporate multi-
ple chemical strategies to enhance hybridization to target
mRNA and/or to reduce toxicity. A second and perhaps
more significant problem, that has impeded the practical
application of the theoretical potential of the antisense
approach, is the difficulty in delivering oligonucleotide
drugs to the target tissue in amounts large enough to be
efficacious but small enough to be without significant toxi-
city. Local delivery represents one way to solve this
problem, and its effectiveness is exemplified by
Fomivirsen™, the first commercially available antisense
oligonucleotide [4]. As we show below, respirable anti-
sense oligonucleotides (RASONs) represent a particularly
attractive form of local delivery, creating an exciting oppor-
tunity for the development of an array of new pharmaceuti-
cals targeting respiratory diseases [5].
RASONs
One problem that has hindered the development of anti-
sense therapeutics is that parenteral administration of
these drugs has required high doses for acceptable levels
of efficacy in the target tissue because the target tissue is
generally distant from the point of administration. Non-anti-
sense side effects related to backbone modifications (eg
hypotension with phosphorothioate backbones), to spe-
cific sequence motifs (eg gene activation by quartets of
guanine base occurring within the oligonucleotide), or to
immune stimulation (unmodified cytosines occurring 5¢ to
guanines stimulate B cell mediated immunosurveillance)
occur in a dose-dependent fashion, a factor that suggests
strongly that minimum efficacious doses should be used.
The lung offers an exceptional target for antisense oligonu-
cleotide delivery. RASONs can be delivered directly to the
target tissue, by inhalation, thereby achieving a bolus dose
directly to the target site. The lung is also uniquely lined
with surfactant, a material that seems to substantially
enhance the uptake and distribution of oligonucleotides
throughout the pulmonary tissues. How might surfactant
contribute to oligonucleotide uptake and distribution? Sur-
factant is primarily composed of zwitterionic lipids that at
lung pH have cationic properties. Cationic lipids are very
well known to enhance the uptake of oligonucleotides into
cells [6]. In fact, it is often difficult to obtain cellular perme-
ation of oligonucleotides under conditions in vitro without
the addition of cationic lipids [7]. When oligonucleotides
are inhaled, they seem to be adsorbed by surfactant, result-
ing in a reformulation of the oligonucleotide in such a way
as to make it amenable to facile uptake within the cells and
tissues of the respiratory tract. Autoradiograms of inhaled
RASONs indicate that penetration occurs even to the
deeper tissues of the lung, and surgical dissection ofc
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bronchial smooth muscle to primary, secondary and tertiary
bronchi in RASON-treated animals, followed by quantifica-
tion of target receptors, confirms this [8•]. The end result of
such surfactant-facilitated uptake of oligonucleotides is a
rather marked reduction in what constitutes an effective
dose. RASONs have been found to be effective at doses
several orders of magnitude less than is usual for other
forms of parenteral administration. The mechanism of this
interaction between surfactant and an inhaled oligonu-
cleotide have not been elucidated in detail, but probably
involve processes more complex than the simple adsorp-
tion on cationic lipids observed under conditions in vitro.
One problem that has plagued traditional pulmonary drugs
is that it has been difficult to limit their effects to the lung.
Systemic toxicity is the dose-limiting consideration for a
large number of respiratory drugs currently on the market,
and was the cause of discontinued development for many
others. RASONs offer a potential solution to this problem
as well, because their nuclease sensitivity can be titrated
by altering their chemistry to make them sufficiently nucle-
ase resistant to be effective, but not so nuclease resistant
that they could escape the lung undegraded. With the use
of this strategy, RASONs are available for hybridization to
their target, but then are degraded before they can enter
the wider circulation. Alternatively, RASONs can be
designed to augment their nuclease resistance substan-
tially, permitting systemic delivery to occur after their
inhalation. Although the design of such ‘super-resistant’
oligonucleotides would permit the targeting of receptors
found in the periphery, this strategy eliminates the advan-
tage of reduced systemic toxicity that less nuclease-resis-
tant inhaled RASONs offer.
RASONs thus seem to offer an effective solution to the
problem of how to deliver just enough oligonucleotide to
the target tissue to attenuate the target mRNA effectively
without producing systemic toxicity.
EPI-2010
EPI-2010 is a 21-mer phosphorothioate RASON targeting
the adenosine A1 receptor. It functions by degrading the
mRNA of the adenosine A1 receptor, preventing the syn-
thesis of new receptor protein. There is therefore a lag
between the administration of EPI-2010 (estimated to be
less than 12 h) and sufficient loss of preformed receptor
protein to obtain a biological response.
Adenosine is thought to be an important mediator of
asthma, and the adenosine A1 receptor is an important
target for asthma therapeutic intervention, for several
reasons:
1. Adenosine levels are above normal in the bronchial
lavage fluid of asthmatic patients [9] and in animal
models of asthma [10].
2. Adenosine upregulation has been shown to be suffi-
cient to induce a powerful inflammatory response in
mice [11••].
3. Asthmatic patients and animals show hypersensitivity
to inhaled adenosine [12••].
4. Adenosine A1 receptor levels are upregulated both in
asthmatic patients [13•] and in animal models of
asthma [14].
5. Adenosine A1 receptor levels are upregulated in
bronchial smooth muscle cells as one of the earliest
responses to antigen stimulation [15•].
6. Adenosine A1 receptor is involved in all three of the
major sequelae of asthma: bronchoconstriction, inflam-
mation, and surfactant depletion [16].
Traditional drugs targeting the adenosine A1 receptor
have not been successfully developed, despite large com-
mitments of time and expense, primarily owing to systemic
toxicity of these drugs. The RASON approach might make
possible the successful attenuation of such difficult
targets because of the ability to design into oligonu-
cleotide structures sufficient nuclease sensitivity to ensure
almost total pulmonary degradation. Such pulmonary
degradation should prevent any non-pulmonary antisense-
mediated attenuation of the target receptor, although it
might not inhibit any toxicities associated with the chemi-
cal nature of the oligonucleotide (eg the phosphorothioate
or other backbone chemistry employed).
EPI-2010 targets the initation codon of the adenosine A1
receptor mRNA (–9 to +11), and is one of the most effec-
tive antisense oligonucleotides ever reported in a setting
in vivo [8•]. We have shown that aerosolized EPI-2010
potently and selectively attenuates adenosine A1 receptor
expression in vivo. It is effective at single delivered inhaled
doses on the order of 50 mg/kg. The half life of EPI-2010
in the lung is less than 24 hours, but its duration of effect
(its ability to block hyper-responsiveness to inhaled adeno-
sine) is 6.8 days (range 4–11 days). This disparity sug-
gests that aspects of the target such as quantity and
half-life of the target mRNA, and/or the quantity and half-
life of the protein for which the mRNA codes, have a major
role in determining the effectiveness of the RASON
approach toward a specific target. EPI-2010 is now
undergoing phase I clinical trials.
Primate models of human asthma
One aspect of the RASON approach that is potentially
problematic is that oligonucleotide-based medicines are
species-specific, in that variations in the DNA sequence of
genes increase as phylogenetic distance increases. Thus,
animal models are generally not applicable to pharmaco-
Available online http://respiratory-research.com/content/2/1/005logical testing of RASONs designed for use in humans.
Even single-base non-homologies are sufficient to reduce
the hybridization potential markedly. Differences between
the target human sequence and the corresponding
sequence in an animal model can be accommodated only
by using antisense oligonucleotides having a sequence
structure completely homologous to that of the animal.
Only in rare circumstances is the human sequence identi-
cal to that for an animal used in a model system, unless
the animal is a primate. Only primates have consistently
high levels of homology to human DNA; for example,
cynomolgus monkey DNA is at least 97.8% homologous
to that of humans. Primate models of human disease are
therefore much preferred for the pharmacological testing
of new antisense constructs, not only because non-human
primate disease might mimic human disease more closely,
but also because antisense constructs designed against
human genes will show complete homology to the non-
human primate gene with much greater consistency than
for any other species. EpiGenesis has created the TruPri-
mate™ model of human asthma to address this need.
RASON-based target validation
The combination of the RASON approach and the TruPri-
mate™ model can also be used to validate or invalidate
putative respiratory targets. For example, techniques such
as differential display can be used to identify genes whose
pulmonary expression seems to be anomalous in the
disease state in comparison with the healthy state, and
RASONs can be used to attenuate the expression of the
anomalously expressed gene. Pulmonary function test
results before and after RASON intervention can then be
assessed to determine whether or not the anomalously
expressed gene is an appropriate subject for the initiation
of a drug discovery program.
One important criterion for accurate target validation, not
only in the respiratory tract but also in the central nervous
system (CNS) and elsewhere, is that the antisense
oligonucleotides used in the process should cleanly ablate
the function of the targeted gene product without inducing
obfuscating side effects. When oligonucleotides are
degraded, they release nucleotides and nucleosides of all
four major bases (adenine, guanine, cytosine, and thymi-
dine/uridine). The release of adenosine as an oligonu-
cleotide degradation product is of extreme concern
because of adenosine’s major role in a host of physiologi-
cal processes ranging from vasoconstriction to control of
sinoatrial rhythm [16,17].
The release of bioactive adenosine from oligonucleotide
degradation can have very important consequences in
hyper-responsive airways and also in applications involv-
ing the CNS (either direct microinjection into specific
brain regions, or intrathecal administration). For example,
individuals with asthma show a nearly universal hypersen-
sitivity to inhaled adenosine and adenosine monophos-
phate, and adenosine released as a product of antisense
oligonucleotide breakdown is capable of activating this
response. (An exception is EPI-2010, in which the recep-
tor mediating adenosine sensitivity is downregulated by
RASON administration and is therefore not available for
adenosine stimulation). The administration of a RASON
containing adenosine might thus cause dose-limiting bron-
choconstriction during the process of oligonucleotide
degradation.
Similarly, the release of adenosine into the CNS during
antisense oligonucleotide degradation can cause the stim-
ulation of any or all of the four adenosine receptors (A1,
A2A, A2B, or A3), potentially causing effects in any of the
more than 40 different physiological processes in which
these receptors have a role in the CNS [16,17]. Such
effects, occurring in parallel to the functional gene ablation
caused by the antisense oligonucleotide, could obscure
the effects of the antisense oligonucleotide, preventing
meaningful target validation data from being obtained.
To avoid this problem, EpiGenesis has developed
desAdenosine™ EpiGene Screen™ antisense oligonu-
cleotides, which do not release adenosine when they are
degraded and therefore cannot modulate the activity of
adenosine receptors. This technology is being applied to
validate or invalidate putative drug discovery candidate
targets in both the respiratory tract and the CNS.
Conclusions
Inhaled RASONs might permit the therapeutic potential of
the antisense approach to be realized in a consistent way.
The unique presence of surfactant in the lung probably
underlies this consistency, because surfactant, in the
manner of cationic lipids, seems to facilitate the pulmonary
uptake and distribution of inhaled oligonucleotides. Two
potential advantages of the RASON approach over tradi-
tional respiratory medicines include an attenuation of the
disease process at a point more proximal to its cause, the
anomalously expressed gene, and a reduction in systemic
side effects owing to the ability to engineer RASONs such
that they are not likely to leave the lung in an undegraded
form. Although not every gene relevant to respiratory
disease might have characteristics amenable to attenua-
tion by the antisense approach, RASONs have the poten-
tial to markedly improve therapeutic outcomes in a wide
array of such diseases.
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